Infliximab for immunotherapy-related kidney injury
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether the drug infliximab can help treat kidney damage caused by immunotherapy (checkpoint inhibitors). It is for people whose kidneys suddenly fail due to inflammation, and who haven't already had strong immune-suppressing treatment for this problem.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You developed acute kidney injury (sudden damage to your kidneys) within 6 months of starting a checkpoint inhibitor immunotherapy drug.
- Your kidney injury is believed to be caused by inflammation (acute interstitial nephritis), either proven by biopsy or strongly suspected by your doctor.
- You have not taken high-dose steroids (more than 10 mg prednisone daily) or other strong immune-suppressing drugs like infliximab within the last 2 weeks.
- You do not have any uncontrolled serious infections (like active tuberculosis, hepatitis B or C, or HIV that is not well-controlled).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called cilastatin can prevent kidney damage caused by certain strong medications. If you are receiving one of these medications and are at risk for kidney injury, this trial may offer protection.
This trial tests whether prednisolone (a steroid medicine) helps people with acute interstitial nephritis, a sudden inflammation of the kidney tissue. You may qualify if your diagnosis was confirmed by kidney biopsy and your kidney function has worsened recently.
This trial compares removing the kidney tumor right away versus waiting, while both groups receive the immunotherapy drugs ipilimumab and nivolumab. It is for people with advanced kidney cancer that has spread to other parts of the body.
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
This trial tests an investigational drug (STR-P004) given by IV to treat kidney diseases caused by the immune system. It aims to see if the drug is safe and tolerable for patients with conditions like lupus nephritis or ANCA vasculitis.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.